The effect of immunomodulative drugs on ADCC was examined by a plaque assay, since ADCC was reported to be affected in some skin diseases. Monocyte-depleted effector lymphocyte (K cell) from human peripheral blood, target sheep red blood cell (SRBC) and anti-SRBC IgG were added to a poly-L-lysine treated microtestplate, and immediately after making monolayers, incubated at a 37°C for 3 hours. The number and the size of hemolytic plaque (HP) of SRBC were examined in the presence of drug and/or culture medium. In absence of the drug, the percentage of plaque forming cell (%PFC) was 6.3±0.4, and the size of HP was 53.4±1.3
μm
2. The treatment of effector lymphocytes with recombinant interferon-
αA (rIFN-
αA) resulted in the augmentation of activity of individual K cell (2×10 U/ml of rIFN-
αA: HP 76.0±2.6
μm
2, p<0.001), but not in the increase of number of K cell, at any concentration. Enhancement of both %PFC and HP was induced by unique immunopotentiators Staphylococcal phage lysate (SPL) and Vaccina virus products (NSP). (2×10 U/ml of SPL: %PFC 10.4±0.6, p<0.001. HP 65.8±2.0
μm
2, p<0.001; 1×10
μg/ml of NSP: %PFC 8.9±1.1, p<0.05, HP 67.2±1.8
μm
2, p<0.001). On the contrary, prednisolone (PS) suppressed the number of K cells, dose dependently (1×10
μg/ml of PS: %PFC 3.0±0.8, p<0.01). The average area of HP was significantly smaller (HP 43.6±1.3
μm
2, p<0.001). Methyl B
12 induced no significant changes on ADCC. Thus, the plaque assay is valuable to elucidate the effect of immunomodulative drugs on ADCC.
View full abstract